Buserelin
Gonadotropin Releasing Hormone Analogues
Sold as SUPREFACT · SUPREFACT DEPOT 2 MONTHS · SUPREFACT DEPOT 3 MONTHS
- Drug class
- Gonadotropin Releasing Hormone Analogues
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 2
- Products on record
- 2
Overview
Buserelin is an active pharmaceutical ingredient in the Gonadotropin Releasing Hormone Analogues group (L02AE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | March 6, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
1 product
Uses
Pituitary desensitisation in preparation for ovulation induction regimens using gonadotrophins.
How to take
CACanada· Health Canada
1 product
Uses
AND CLINICAL USE ............................................................................... 3 CONTRAINDICATIONS .................................................................................................... 4 WARNINGS AND PRECAUTIONS ...................................................................................
5 ADVERSE REACTIONS................................................................................................... 10 DRUG INTERACTIONS ...................................................................................................
17 DOSAGE AND ADMINISTRATION ............................................................................... 18 OVERDOSAGE .................................................................................................................
20 ACTION AND CLINICAL PHARMACOLOGY ............................................................. 20 STORAGE AND STABILITY ........................................................................................... 22 DOSAGE FORMS, COMPOSITION AND PACKAGING ..............................................
Sources & citations
- [1]MHRA (UK) · PL450430051 · revised March 6, 2026
- [2]Health Canada (DPD) · 02225166 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.